Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEG-002 iPS cell-derived platelet transfusion study in thrombocytopenia
jRCT2053210068Completed
- Sponsor
- Megakaryon Corporation
- Start
- Aug 2021
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of human-induced pluripotent stem cell-derived platelets in Thrombocytopenia (2 arms), sponsored by Megakaryon Corporation. Primary endpoints: Safety and Efficacy. Started Aug 2021; status: completed.
02
Drugs
human-induced pluripotent stem cell-derived platelets
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on jRCT2053210068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053210068.